Integra LifeSciences Announces First Clinical Uses of Cadence™ Total Ankle System in Europe
September 20 2016 - 8:30AM
Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading
global medical technology company, today announced that the first
three procedures using the Integra® Cadence™ Total Ankle System in
Europe were successfully completed since July 13, 2016 by Dr.
Thibaut Leemrijse, of the Foot and Ankle Institute, Parc Léopold
Clinic, Brussels, Belgium. Internationally renowned for his
expertise in foot surgery, Dr. Leemrijse and his team are
considered leaders in the field of ankle arthroplasty.
“Integra’s new Cadence system offers a two-component implant,
designed to adapt to a patient’s anatomy by providing improved
range of motion, intraoperatively,” said Dr. Leemrijse. “The
instrumentation allows ideal positioning of the implant, and the
learning curve for this new device seems short, based on our first
cases.”
The European introduction of the Cadence system supports
Integra’s role as a leader in this rapidly expanding market. New
and improved designs and advanced surgical education programs, such
as the ones developed by Integra, are fueling the growth of the
ankle prosthesis segment.
“Our innovative arthroplasty device is an example of the close
cooperation between our company and expert surgeons, which seeks to
develop devices that can be efficiently implanted in various
anatomies,” said Stéphane Corp, Integra’s Vice President,
Orthopedics & Tissue Technologies, for Europe, Middle East and
Africa.
The Cadence system's differentiated anatomic design and
streamlined surgical technique allow Integra to continue offering a
complete set of options to treat the continuum of care in total
ankle prosthesis, one of the fastest growing extremities
segments.
About IntegraIntegra LifeSciences, a world
leader in medical technology, is dedicated to limiting uncertainty
for clinicians, so they can concentrate on providing the best
patient care. Integra offers innovative solutions, including
leading plastic and regenerative technologies, in specialty
surgical solutions, orthopedics and tissue technologies. For more
information, please visit www.integralife.com.
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include, but are not limited to,
statements concerning the products and services provided by
Integra. Such forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially
from predicted or expected results. Among other things, the
willingness of surgical professionals to use Integra products may
affect the prospects for their use in surgical procedures. In
addition, the economic, competitive, governmental, technological
and other factors, identified under the heading "Risk Factors"
included in Item IA of Integra's Annual Report on Form 10-K for the
year ended December 31, 2015 and information contained in
subsequent filings with the Securities and Exchange Commission
could affect actual results.
CONTACT: Integra LifeSciences Holdings Company
Investors
Angela Steinway
609-936-2268
angela.steinway@integralife.com
Michael Beaulieu
609-750-2827
michael.beaulieu@integralife.com
Media Europe
Marie-Anne Girel
marie-anne.girel@integralife.com
Media U.S.
Gianna Sabella
609-775-8553
gianna.sabella@integralife.com
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From Mar 2024 to Apr 2024
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From Apr 2023 to Apr 2024